BioVaxys Technology Corp.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- James Christopher Passin
- Full Time Employees
- 3
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 905 West Pender Street Etobicoke BC Canada V6C 1L6
- IPO Date
- Dec 28, 2018
- Website
- biovaxys.com
- Similar Companies
- Business
- I did a web search but did not find direct recent news or changes specifically for BioVaxys Technology Corp. (Ticker: BVAXF). I will now search specifically about BioVaxys Technology Corp.’s business activities, products, services, and any recent updates or developments to gather relevant detailed information.
BioVaxys Presents Further Validation of the Robust Immune Response from a Combination of MVP-S with Checkpoint Inhibitors and Low-Dose Cyclophosphamide in Ovarian Cancer
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
BioVaxys Announces Phase I/II PESCO Trial Abstract Accepted for Presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
BioVaxys Announces Application for Management Cease Trade Order
BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer
BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)
BioVaxys 1Q2026 R&D and Collaborative Activity
BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer
2025 Corporate Review
BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer
BioVaxys Strengthens Scientific Team with Addition of Former IMV Vice President of R&D
BioVaxys Technology Corp. Closes Debt Settlement Transaction
BioVaxys Technology Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement
BioVaxys Technology Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement
BioVaxys Licensee SpayVac-for-Wildlife, Inc., Reports Further Positive Single-Dose Efficacy Data for Its Immunocontraceptive Vaccine and Initiation of Regulatory Submission Process
CSE Bulletin: Consolidation - BioVaxys Technology Corp. (BIOV)
BIOVAXYS ANNOUNCES SHARE CONSOLIDATION